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Demonstration of the Recurrence of Marfan-like
Skeletal and Cardiovascular Manifestations Due to
Germline Mosaicism for an FBN1 Mutation
To the Editor:
Marfan syndrome (MFS [MIM 154700]) is a dominantly
inherited disease of connective tissue. Cardinal manifes-
tations involve the eye (lens dislocation and myopia),
skeleton (dolichostenomelia, arachnodactyly, anterior
chest deformity, spinal curvature, and joint laxity) and
cardiovascular system (aortic root dilation and dissec-
tion, mitral valve prolapse, and mitral and aortic valve
regurgitation). Striae distensae and inguinal hernia are
frequent findings in the integument, and pneumothorax
and dural ectasia occur in some patients (Pyeritz and
McKusick 1979; First International Symposium on the
Marfan Syndrome 1989). If untreated, the syndrome
shortens life expectancy mainly because of cardiovas-
cular complications. The disorder is characterized by
considerable variation in the distribution and severity of
organ system involvement between families, leading to
the definition of diagnostic criteria listed first in the Ber-
lin nosology (Beighton et al. 1988) and subsequently
revised in the Ghent nosology (de Paepe et al. 1996). In
1986, Sakai and colleagues identified a 350-kD glyco-
protein called “fibrillin,” which represents the major
structural component of connective tissue microfibrils.
By using an anti-fibrillin antibody, Godfrey, Hollister,
and their colleagues demonstrated a reduction of mi-
crofibrils in immunofluorescence studies of cultured der-
mal fibroblasts in patients with MFS (Godfrey et al.
1990; Hollister et al. 1990). Subsequent studies of fi-
brillin synthesis, secretion, and incorporation into the
extracellular matrix showed abnormalities in most but
not all MFS fibroblast strains (Milewicz et al 1992; Col-
lod et al. 1994). Finally, mutations in the FBN1 gene,
encoding fibrillin, have been demonstrated to result in
MFS or associated phenotypes (Dietz et al. 1991; Hay-
ward et al. 1994; Kainulainen et al. 1994; Lonnqvist et
al. 1994; Sood et al. 1996). The FBN1 gene is ∼200 kb
in size, with a coding sequence fragmented into 65 exons
(Corson et al. 1993; Pereira et al. 1993; Biery et al. 1999)
located on chromosome 15q21.1 (Magenis et al. 1991).
918 Letters to the Editor
It encodes a large glycoprotein composed of repeated
modules, 47 of which are homologous to human epi-
dermal growth factor (EGF) (“EGF-like modules”) and
are interspersed by seven modules displaying high ho-
mology to transforming growth factor b1–binding pro-
tein (TGFb1-bp), (“8-cysteine modules”) (Corson et al.
1993; Pereira et al. 1993). To date, 1160 FBN1 muta-
tions in patients with MFS or associated phenotypes
have been reported or submitted in the Marfan Database
(Collod et al. 1996; Collod-Be´roud et al. 1997, 1998).
However, hardly any predictions of the resulting phe-
notype can yet be made on the basis of the nature of a
specific mutation.
The prevalence of MFS has been estimated at 1/5,000,
and 25% of patients represent sporadic cases. This
high mutation rate should be associated with cases of
germline mosaicism, as has been reported in other con-
nective-tissue disorders or other genetic disorders with
a high mutation rate. Therefore, it was surprising that,
until recently (Montgomery et al. 1998; Rantamaki et
al. 1999), no instance of somatic or germline mosaicism
had been reported in MFS. Furthermore, since FBN1
mutations are also associated with phenotypes overlap-
ping MFS, mosaicism could also be identified in these
subtypes. In this report, we demonstrate somatic mo-
saicism of a FBN1 genomic mutation in the father of
two siblings who presented with the typical skeletal and
cardiovascular features observed in the Marfan syn-
drome.
The proband, MS48MA307, was identified at the
Centre Hospitalier in Amiens (by M.M. and Y.M.), and
his family was investigated at the Marfan Clinic at Am-
broise Pare´ Hospital, Boulogne (by G.J.). The diagnostic
criteria used were those reported by Beighton et al.
(1988). The parents of MS48MA307 and his brother,
MS48MA308, were unaffected. Patient MS48MA307,
a 16-year-old boy, presented dilation of the ascending
aorta (46 mm at the sinuses of Valsalva, 8 SD above the
mean when standardized to age and body surface area),
mitral valve prolapse with regurgitation, highly arched
palate, arachnodactyly (positive wrist and thumb signs),
tall stature (199 cm, 4 SD, 76 kg), and scoliosis. His
9-year-old brother (MS48MA308) displayed dilation of
the ascending aorta (32 mm at the sinuses of Valsalva,
6 SD above the mean when standardized to age and body
surface area), arachnodactyly (positive wrist and thumb
signs), dolichostenomelia (arm span–to-height ratio
1.05), tall stature (144 cm,3 SD, 31 kg), highly arched
palate, and joint hypermobility. No other typical anom-
aly of MFS (including ectopia lentis) was found in either
subject. Both parents were examined thoroughly, and
the diagnosis of MFS was excluded for both. Blood sam-
ples were collected from the four family members and
from 150 unrelated French subjects. DNA was extracted
from white blood cells (Henry et al. 1984). Informed
consent was obtained for all individuals. Sense and an-
tisense primers designed from flanking intron sequences
were used for PCR amplification of exons 1–65 of FBN1
and were described, along with PCR amplification con-
ditions, in Nijbroek et al. (1995). SSCP analysis of the
FBN1 gene from white blood cells revealed an abnormal
pattern for the 419-bp fragment of exon 24 for patient
MS48MA307. This abnormal pattern was also identified
in his brother, MS48MA308, but was absent in the
mother. However, the father presented a very slight ab-
normal pattern (fig. 1a). Paternity and maternity had
been tested previously and indirectly by analysis of
highly polymorphic markers on chromosomes 3, 5, and
15 (data not shown). The abnormal fragment from the
SSCP gel was cut out of the gel, and DNA was eluted
in water and reamplified by PCR. The PCR product was
purified with the Promega Wizard Prep kit and was di-
rectly sequenced on both strands by means of a cycle-
sequencing kit (Pharmacia). Sequencing revealed that the
two boys carried the identical heterozygous 2954 GrA
transition that results in a GlyrGlu change at codon
985 (G985E) (fig. 1d). There is a compelling body of
evidence to suggest that G985E is indeed a disease-pro-
ducing mutation. First, this alteration was not observed
during screening of 306 chromosomes. Second, the mu-
tation substitutes an uncharged for a negatively charged
amino acid of much higher molecular weight. Finally,
the mutational event occurs in the 8-cysteine module 3
at a position conserved in the bovine, murine, and por-
cine sequences.
Since MFS is characterized by a high mutation rate,
the recurrence of the disease in the sibs could have been
due to two unrelated de novo mutations. However, since
mutations in the FBN1 gene are essentially private, the
presence of an identical mutation in the brothers sug-
gested that the most likely hypothesis was that the mu-
tation had been inherited from one of the parents. Since
the mutation creates a new TaqI restriction site resulting
in two fragments of 202 and 217 bp, it could easily be
looked for in the family (fig. 1b). After transfer on Hy-
bond N membrane (Amersham) and hybridization
with the sense primer, the 217-bp fragment resulting
from digestion was found in the father’s white blood
cell DNA (MS48MA305), at a very low level, but was
not found in that from the mother (MS48MA306) or in
three controls (fig. 1c). The finding of the alteration in
the father’s white blood cells and the recurrence of the
disease in his children implied somatic and germline mo-
saicism in the father. Careful reassessment of clinical
examination of the father (performed systematically be-
fore the identification of the mosaicism) revealed no skel-
etal or ocular sign but minor findings: discreet dilation
of the ascending aorta (43 mm, 2 SD when standard-
ized to age and body surface area [193 cm, 75 kg, at
age 41 years]) and minimal aortic regurgitation. This
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Figure 1 a, DNA single-strand analysis by nondenaturing PAGE (SSCP) of a 419-bp PCR product including exon 24. Aberrant migration
of PCR product is found in subjects MS47MA307 and MS47MA308 compared with their parents and the normal control. b, The GrA transition
creates a TaqI site within the 419-bp PCR product of exon 24, resulting in two fragments of 202 and 217 bp. TaqI digestion confirmed the
G985E mutation in the two brothers MS47MA307 and MS47MA308. c, The digestion products were migrated and then were hybridized with
the sense primer. Only the PCR product resistant to digestion can be found for normal controls 1, 2, and 3 and for the mother (MS47MA306).
The heterozygous three-banded restriction enzyme pattern after TaqI digestion is present for MS47MA307 and the father MS47MA305, after
overexposure. d, The normal (for MS47MA306) and abnormal (for MS47MA307) fragments from the SSCP gel (in a, above) were cut, eluted
in water, and reamplified by PCR. Sequencing for MS47MA307 compared with normal sequence (MS47MA306) revealed a GrA transition at
nucleotide position 2954, resulting in a GlyrGlu change at codon 985 (G985E).
mutation probably arose at an early mitotic stage in
embryonic development, as reflected by distribution in
somatic and germ cell tissues.
The MFS-like phenotype associated with the G985E
mutation in exon 24 is not associated with ocular anom-
alies. Of interest, the Marfan Database (Collod-Be´roud
et al. 1998), when sorted for mutations in MFS patients
who have no ocular anomaly, indicates that half (9/19)
of these mutations are located in exons 23–29. This con-
trasts with mutations associated with the complete clas-
sic MFS, which are widely distributed throughout the
gene. Furthermore, study of the distribution of muta-
tions identified in 8-cysteine modules after their align-
ment by their consensus sequence indicates that the
G985E mutation affects a residue close to three consec-
utive cysteines. This region harbors three other muta-
tions (5137ins4 [Dietz et al. 1993], C1721Y [Collod-
Be´roud et al. 1998], and V984I [Collod-Be´roud et al.
1998]) identified in probands that do not have ectopia
lentis. The 8-cysteine modules are found only in fibrillins
and latent TGFb1-bp, and their function in fibrillins is
still unclear. The absence of ectopia lentis and, therefore,
the probable absence of major zonular alteration in sub-
jects carrying mutations in this region of the 8-cysteine
modules would tend to indicate the absence of a specific
function of this module in the zonule.
Our observation shows that somatic and germline mo-
saicism are associated with MFS-like features and should
be looked for in parents of sporadic cases presenting
with these MFS-like features. In effect, if mild or isolated
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features of the disease are found in one of the parents,
genetic counseling should take into account the possible
presence of the disease in another child. Somatic mo-
saicism could also explain the mild and incomplete fea-
tures often seen in patients referred to MFS clinics for
diagnosis. Again, caution is warranted in the follow-up
of these patients and in evaluation of the risk of trans-
mission.
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The Jewish Ashkenazi Founder Mutations in the
BRCA1/BRCA2 Genes Are Not Found at an Increased
Frequency in Ashkenazi Patients with Prostate Cancer
To the Editor:
BRCA1 and BRCA2, the predisposing genes for breast
cancer (BC) and ovarian cancer (OC), have been sug-
gested to increase the risk of prostate cancer (PrC) in
male carriers (Ford et al. 1994; Thorlacius et al. 1996;
Struewing et al. 1997); however, no direct evidence exists
to confirm this hypothesis. A population with a high
carrier frequency of BRCA1 and BRCA2 germinal mu-
tations allows a direct approach to studying the role
BRCA1 and BRCA2 play in the development of PrC; if
germinal mutations in BRCA1 and BRCA2 increase the
risk of PrC in carriers, it is to be expected that the carrier
frequency in PrC patients will be higher than in the gen-
eral population, as was demonstrated in female patients
diagnosed with BC and OC (Ford et al. 1995; Claus et
al. 1996, Abeliovich et al. 1997).
In the Ashkenazi Jewish population, three founder
mutations, 185delAG and 5382insC in the BRCA1 gene
and 6174delT in the BRCA2 gene, exist at a high fre-
quency (2.5%) (Struewing et al. 1995; Oddoux et al.
1996; Roa et al. 1996; Fodor et al. 1998). To assess the
contribution of the BRCA1/BRCA2 germinal mutations
to PrC morbidity, we analyzed the Ashkenazi founder
mutations in two groups (with the same age distribution)
of Ashkenazi men, a group of unselected PrC patients,
and a control group of men with no history of cancer.
The study was designed around the fact that, in families
known to segregate BRCA1/BRCA2 mutations, men
with PrC were noted sporadically. It was thus assumed
that, if BRCA1 and BRCA2 play a role in the devel-
opment of PrC, they do so as risk modifiers rather than
as major dominant genes, and therefore will not be con-
fined to familial cases.
Patients diagnosed with adenocarcinoma of the pros-
tate ( ) were recruited from the oncology outpa-n = 87
tient clinic at Sharett Institute, Hadassah Hebrew Uni-
versity Hospital, with no preselection. The patients
signed an informed-consent form approved by the hos-
pital’s ethics committee. Each patient was interviewed
regarding his family history. Clinical and pathological
records were the sources of the clinical data.
The control group included 87 healthy men with no
history of cancer. These men were approached in Jeru-
salem-area homes for the elderly and were asked to par-
ticipate in the study; if they agreed, they signed an in-
formed-consent form. Their blood samples were kept
anonymous, labeled only with the patients’ ages and
origins (table 1). The median age was 71 years at the
time of diagnosis for the patients with PrC and 72 years
at the time of blood sampling for the control group (table
2). The mutations were analyzed as described elsewhere
(Abeliovich et al. 1997).
The risk of developing PrC is age-dependent and is
determined by differential exposure to environmental
factors. In addition, positive family history is a major
risk factor for developing PrC at an early age (Steinberg
et al. 1990; Spitz et al. 1991; Whittemore et al. 1995).
It is assumed that ∼10% of all cases of PrC and half of
the cases diagnosed at an early age (!60 years) are dom-
inantly inherited. Linkage analyses in families with mul-
tiple cases of PrC pointed to a PrC-susceptibility gene
(or group of genes) on chromosome 1 (Smith et al. 1996;
Gro¨nberg et al. 1997a; Berthon et al. 1998; Schaid et
al. 1998), and, recently, an X-linked gene was suggested
(Xu et al. 1998). It can be argued that BRCA1 and
BRCA2 markedly reduce the age at onset of PrC and
that therefore the effect of BRCA1/BRCA2 will be
shown only in patients diagnosed with PrC at age !60
years, whereas in our study only five patients were as-
certained in this age group. However, since 2.5% of
Ashkenazi males are BRCA1/BRCA2 carriers, it would
be expected that an excess of Ashkenazi men will de-
velop PrC at age !60 years. The stratification of the ages
